These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 15317885)

  • 1. Viral entry denied.
    Doms RW
    N Engl J Med; 2004 Aug; 351(8):743-4. PubMed ID: 15317885
    [No Abstract]   [Full Text] [Related]  

  • 2. 2-deoxy-D-glucose as a potential drug against fusogenic viruses including HIV.
    Parris GE
    Med Hypotheses; 2008; 70(4):776-82. PubMed ID: 17920779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Entry of Semliki forest virus into cells: effects of concanamycin A and nigericin on viral membrane fusion and infection.
    Irurzun A; Nieva JL; Carrasco L
    Virology; 1997 Jan; 227(2):488-92. PubMed ID: 9018148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
    Takashima K; Miyake H; Furuta RA; Fujisawa JI; Iizawa Y; Kanzaki N; Shiraishi M; Okonogi K; Baba M
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3538-43. PubMed ID: 11709336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 gp41: mediator of fusion and target for inhibition.
    Weiss CD
    AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of recombinant vesicular stomatitis viruses encoding mutant glycoproteins demonstrate a critical role for maintaining a high pH threshold for membrane fusion in viral fitness.
    Fredericksen BL; Whitt MA
    Virology; 1998 Jan; 240(2):349-58. PubMed ID: 9454708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Entry inhibitors: a race to the finish line.
    Proj Inf Perspect; 2006 Jan; (40):7-12. PubMed ID: 16718905
    [No Abstract]   [Full Text] [Related]  

  • 8. Antiviral activity of membrane fusion inhibitors that target gp40 of the feline immunodeficiency virus envelope protein.
    Mizukoshi F; Baba K; Goto Y; Setoguchi A; Fujino Y; Ohno K; Oishi S; Kodera Y; Fujii N; Tsujimoto H
    Vet Microbiol; 2009 Apr; 136(1-2):155-9. PubMed ID: 19036536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects of HIV-1 entry inhibitors as novel therapeutics.
    Pierson TC; Doms RW; Pöhlmann S
    Rev Med Virol; 2004; 14(4):255-70. PubMed ID: 15248253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heptad repeat 2 in herpes simplex virus 1 gH interacts with heptad repeat 1 and is critical for virus entry and fusion.
    Gianni T; Piccoli A; Bertucci C; Campadelli-Fiume G
    J Virol; 2006 Mar; 80(5):2216-24. PubMed ID: 16474129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A sensitive HIV-1 envelope induced fusion assay identifies fusion enhancement of thrombin.
    Cheng DC; Zhong GC; Su JX; Liu YH; Li Y; Wang JY; Hattori T; Ling H; Zhang FM
    Biochem Biophys Res Commun; 2010 Jan; 391(4):1780-4. PubMed ID: 20045672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [HIV lipids--biological role and target for antiviral agents].
    Frolov AF; Vasiurenko ZP
    Mol Gen Mikrobiol Virusol; 1993; (3):3-7. PubMed ID: 8350880
    [No Abstract]   [Full Text] [Related]  

  • 13. Flavonoid baicalin inhibits HIV-1 infection at the level of viral entry.
    Li BQ; Fu T; Dongyan Y; Mikovits JA; Ruscetti FW; Wang JM
    Biochem Biophys Res Commun; 2000 Sep; 276(2):534-8. PubMed ID: 11027509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and characterization of human respiratory syncytial virus entry inhibitors.
    Ni L; Zhao L; Qian Y; Zhu J; Jin Z; Chen YW; Tien P; Gao GF
    Antivir Ther; 2005; 10(7):833-40. PubMed ID: 16312179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].
    Azevedo-Pereira JM; Santos-Costa Q
    Acta Med Port; 2008; 21(5):497-504. PubMed ID: 19187693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The catalytic activity of protein disulfide isomerase is involved in human immunodeficiency virus envelope-mediated membrane fusion after CD4 cell binding.
    Fenouillet E; Barbouche R; Courageot J; Miquelis R
    J Infect Dis; 2001 Mar; 183(5):744-52. PubMed ID: 11181151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Entry denied.
    Puttagunta L
    CMAJ; 2023 Apr; 195(13):E486-E487. PubMed ID: 37011929
    [No Abstract]   [Full Text] [Related]  

  • 18. Lectins Are the Sparkle of Hope for Combating Coronaviruses and the Global COVID-19.
    Abbas HS; Kotakonda M
    Adv Pharm Bull; 2022 Mar; 12(2):319-328. PubMed ID: 35620331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of novel entry inhibitors targeting emerging viruses.
    Zhou Y; Simmons G
    Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1129-38. PubMed ID: 23199399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. X4 Human immunodeficiency virus type 1 gp120 promotes human hepatic stellate cell activation and collagen I expression through interactions with CXCR4.
    Hong F; Saiman Y; Si C; Mosoian A; Bansal MB
    PLoS One; 2012; 7(3):e33659. PubMed ID: 22479424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.